Analysts' Recommendation for CYTK Stock at $67.63

This afternoon we watched Cytokinetics rise 2.4% to a price of $67.63 per share. The Mid-Cap Pharmaceutical company is now trading -29.29% below its average target price of $95.65. Analysts have set target prices ranging from $60.0 to $122.0 per share for Cytokinetics, and have given the stock an average rating of buy.

The stock has an unusually large proportion of its shares sold short at 23.1%, and a short ratio of 7.52. Only 0.88% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 113.8% of Cytokinetics's shares being owned by this investor type.

Institutions Invested in Cytokinetics

Date Reported Holder Percentage Shares Value
2023-12-31 Blackrock Inc. 16% 16,102,070 $1,088,982,949
2023-12-31 FMR, LLC 13% 13,007,783 $879,716,328
2023-12-31 Vanguard Group Inc 11% 11,016,889 $745,072,172
2023-12-31 Wellington Management Group, LLP 6% 6,488,500 $438,817,237
2023-12-31 State Street Corporation 6% 5,893,358 $398,567,785
2023-12-31 Price (T.Rowe) Associates Inc 3% 3,244,250 $219,408,618
2023-12-31 Janus Henderson Group PLC 2% 2,568,405 $173,701,223
2023-12-31 RTW Investments LP 2% 2,525,080 $170,771,153
2023-12-31 Morgan Stanley 2% 2,401,582 $162,418,984
2023-12-31 T. Rowe Price Investment Management, Inc. 2% 2,229,485 $150,780,064

Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Cytokinetics.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.